A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia (LOHKALT)
A Phase IV, Multicentre, Non-comparative, Open-label Study Evaluating the Safety and Effectiveness of Lokelma (Sodium Zirconium Cyclosilicate [SZC]) Administered Orally for the Treatment of Indian Patients With Hyperkalaemia
This is a Phase IV, multicentre, open-label, non-comparative study evaluating Lokelma (sodium zirconium cyclosilicate, SZC) in approximately 100 Indian adults with mild to moderate hyperkalaemia.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The primary objective is to assess safety through treatment-emergent adverse events, serious adverse events and discontinuations due to adverse events. Secondary objectives are to assess effectiveness of Lokelma through serum potassium reduction, achievement and maintenance of normokalaemia, while an exploratory objective focuses on continuation or initiation of RAAS inhibitor therapy. Each participant is followed for approximately 3.5 months, including treatment and a safety follow-up seven days after the final dose.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Ahmedabad, India, 380052
- Recruiting
- Research Site
-
Ahmedabad, India, 380013
- Recruiting
- Research Site
-
Kolkata, India, 700020
- Recruiting
- Research Site
-
Secunderabad, India, 500003
- Recruiting
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
• Participant must be ≥ 18 years of age, at the time of signing the informed consent.
- Participants with mild to moderate hyperkalaemia- the potassium values between 5.1 to 6.4 mmol/L inclusive, at screening (Day 0)
- Ability to have repeated blood draws or effective venous catheterisation.
- Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. i) FOCBP must be using two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at screening. The female participants should be on stable on their chosen method of birth control for minimum of one month before entering the study and willing to remain on the birth control until 7 days after the last dose. ii) Female participants who are surgically sterile or those who are post-menopausal (if they have been amenorrhoeic for 12 months prior to the planned date of screening without an alternative medical cause) are not considered to be of child-bearing potential.
- Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Exclusion Criteria:
-
As judged by the investigator, any evidence of oedema which in the investigator's opinion makes it undesirable for the participant to participate in the study.
- Patients undergoing haemodialysis or a prospective candidate for haemodialysis.
- Pseudo hyperkalaemia signs and symptoms, such as excessive fist clenching haemolysed blood specimen, severe leucocytosis or thrombocytosis.
- Participants with a life expectancy of < 12 months.
- Participants who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the participants' tasks associated with the protocol.
- Women who are pregnant, lactating, or planning to become pregnant.
- Participants with diabetic ketoacidosis.
- Presence of any condition which, in the opinion of the investigator, places the participant at undue risk.
- Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
- Participants with cardiac arrhythmias requiring immediate treatment.
- Participants with history of QT prolongation associated with other medications that required discontinuation of that medication.
- Participants with congenital long QT syndrome.
- Participants treated with lactulose, rifaximin or other non-absorbed antibiotics for hyperammonaemia within the last 7 days.
- Participants treated with resins (such as sevelamer acetate), calcium acetate, calcium carbonate, or lanthanum carbonate, within the last 7 days.
- Participants treated with SPS or SZC (microporous, fractionated, protonated zirconium silicate), CPS or patiromer within the last 7 days.
- Known hypersensitivity or previous anaphylaxis to SZC or to components or any of the excipients of the product.
- Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.
- Prior (within last 1 month) and ongoing participation in another clinical trial, observational study, and real-world evidence study.
- Positive hepatitis C antibody, hepatitis B virus surface antigen, or hepatitis B virus core antibody, at screening.
- Known to have tested positive for HIV.
- Documented glomerular filtration rate < 15 mL/min/1.73 m2 within 90 days before study entry.
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g |
Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of TEAEs, SAEs, and DAEs.
Time Frame: Day 86
|
Number and proportion of participants with TEAEs SAEs, and DAEs. Incidence rates summarised by patients with events per 100 patient-years. |
Day 86
|
|
Causal relationship of TEAEs, SAEs, and DAEs
Time Frame: Day 86
|
Nature, intensity and causal relationship of TEAEs, SAEs, and DAEs |
Day 86
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exponential rate of change in S-K values
Time Frame: Day 4
|
Rate of Change in S-K values |
Day 4
|
|
Proportion of participants who achieve normokalaemia
Time Frame: Day 4
|
Number of study subjects achieving normal potassium levels |
Day 4
|
|
Mean change and mean percent change from baseline in S-K values
Time Frame: Day 86
|
Mean change and mean percent change from baseline in S-K values over time until EOT |
Day 86
|
|
Proportions of participants maintaining normokalaemia
Time Frame: Day 86
|
Number participants maintaining normal potassium levels at EOT |
Day 86
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D9480L00025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.